Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: A longitudinal study

Article (PDF Available)inPsychoneuroendocrinology 37(5):685-92 · September 2011with145 Reads
DOI: 10.1016/j.psyneuen.2011.08.012 · Source: PubMed
We have previously reported that cognitive deficits are cross-sectionally associated with elevated cortisol in depressed patients. Here, we longitudinally examined if changes in cortisol secretion during treatment are associated with improvement of cognition. Cognitive function and salivary cortisol levels were longitudinally examined in 52 patients with major depression before and after 3 weeks of standardized selective serotonin reuptake inhibitor (SSRI) and an add-on treatment modulating the mineralocorticoid receptor and compared to a healthy control group (n=50) matched for age, gender and years of education. Across add-on treatment groups, SSRI treatment reduced salivary cortisol in patients to levels of healthy controls (time×group interaction p=.05). In patients, reduction of cortisol significantly correlated with improvement in depressive symptoms (r=.52, p<.01), speed of information processing (r=.50, p<.01), and cognitive set-shifting (r=.34, p=.03). Improved depressive symptoms were only associated with improved attention and working memory. Improvement of some cognitive domains during SSRI treatment was associated with decreasing cortisol secretion and was only to a lesser extent associated with improved depressive symptoms.


Full-text (PDF)

Available from: Christian Otte
    • "Einer Placebo-Kontrollgruppe bedienten sich bislang, abgesehen von einer kleinen Studie, in der Reboxetin (nicht jedoch Paroxetin) günstige Effekte auf die kognitive Funktionsfähigkeit bei depressiven Patienten gezeigt hat [14], ausschließlich die beiden oben beschriebenen Studien, in denen Vortioxetin verglichen mit Placebo günstige Effekte zeigte [31, 36]. Unklar bleibt, ob Studien, die in einem Test-Retest-Design eine gesunde Kontrollgruppe beinhalteten , zeigen für verschiedene Antidepressiva (Escitalopram, Sertralin, Fluoxetin, Duloxetin) eine gewisse Verbesserung der Kognition depressiver Patienten, die jedoch nicht das Niveau gesunder Kontrollprobanden erreichten [19, 21]. In den meisten Studien wurde jedoch die zweite Testung bereits wenige Wochen nach Behandlungsbeginn durchgeführt, sodass möglicherweise Herrera-Guzman [20] 2008 n = 20 MD* Bupropion (150 mg/Tag) Patienten verbesserten sich im visuellen Gedächtnis und in der Verarbeitungsgeschwindigkeit. "
    [Show abstract] [Hide abstract] ABSTRACT: Due to its high life-time prevalence, major depression is one of the most urging medical problems in public health care. In many depressed patients cognitive dysfunction is present not only during the depressive episode but also as a residual symptom after remission has been achieved. Residual symptoms like cognitive dysfunction impair the patients' social functional level as well as their quality of life and they increase the risk of relapse. Up to now, only few studies have specifically examined the effects of antidepressants on cognitive dysfunction in depressed patients. Vortioxetine is a multimodal antidepressant acting on serotonin (5-HT) receptors in several ways: as an antagonist on 5-HT3, 5-HT7, and 5-HT1D receptors, as a partial agonist on 5-HT1B receptors, and as an agonist on 5-HT1A receptors; furthermore, it inhibits the 5-HT transporter. In preclinical animal studies, vortioxetine showed positive effects on learning and memory. The effects of vortioxetine on cognitive dysfunction in depressed patients are discussed in the context of available studies with other antidepressants. © 2015, Wissenschaftliche Verlagsgesellschaft MBH. All rights reserved.
    Full-text · Article · Jan 2015 · Psychoneuroendocrinology
    • "Saliva has been used to test for cortisol levels as an indicator of chronic stress in healthy patients [83]. Elevated salivary cortisol levels have been identified in depressed patients [84, 85]. Nevertheless, cortisol levels in saliva can suggest other, non-mental health conditions as well, and while its noninvasive nature and ease of collection make salivary diagnostics extremely attractive, much work remains to be done before an effective and reliable screening tool using saliva is available [86]. "
    [Show abstract] [Hide abstract] ABSTRACT: Major depressive disorder (MDD) affects approximately 14.8 million adults in the United States, which is about 6.7 % of the US population. MDD impacts most activities of daily living, including oral hygiene practices and use of dental resources. This review article provides information related to underlying mechanisms of disease, diagnosis, and treatment so that dentists may best address patients’ dental concerns in the context of underlying depression. Laboratory and psychological screening tools are also discussed in relation to specific practice recommendations for managing patients with MDD as well as identifying patients with underlying symptoms who may be at risk for MDD.
    Article · Sep 2014
    • "In particular, the classical " glucocorticoid cascade hypothesis " postulated that chronic stress-related increases in cortisol levels would lead to hippocampal neurotoxic damage and progressive disinhibition of the HPA axis in a feed-forward cycle (Sapolsky et al., 1986 ). Consistent with this, heightened cortisol levels predicted persisting hippocampalrelated cognitive deficits both in younger adults with MDD (Hinkelmann et al., 2012) and in older, non clinically depressed individuals (Lupien et al., 2005; Beluche et al., 2010; Comijs et al., 2010). Instead, in apparent contrast with this hypothesis, two of the studies we included in the metaanalysis assessed the performance in various neuropsychological domains: deficits in memory and "
    [Show abstract] [Hide abstract] ABSTRACT: axis and aging in depression: systematic review and meta-analysis, Psychoneuroendocrinology (2013), This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    Full-text · Article · Dec 2013
Show more